Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | XPO1 | O14980 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | AVPR1B | P47901 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20033899 | 0.93 | NR1I2 (0.40) | NR1I2KDM4EALDH1A1DGAT1SOAT1 | |
| SCHEMBL20344833 | 0.89 | NR1I2 (0.41) | NR1I2PDCD1CD274AVPR1BKMT2A | |
| SCHEMBL17029005 | 0.89 | NR1I2 (0.42) | NR1I2KDM4ESMN1; SMN2PDCD1CD274 | |
| SCHEMBL17029006 | 0.88 | NR1I2 (0.41) | NR1I2KDM4ESMN1; SMN2PDCD1CD274 | |
| SCHEMBL17039259 | 0.87 | NR1I2 (0.39) | NR1I2KDM4ETSHRMAPK1SMN1; SMN2 | |
| SCHEMBL17039244 | 0.87 | NR1I2 (0.42) | NR1I2KDM4ETSHRMAPK1SMN1; SMN2 | |
| SCHEMBL20344788 | 0.87 | NR1I2 (0.42) | NR1I2KDM4ETSHRMAPK1SMN1; SMN2 | |
| SCHEMBL20344789 | 0.84 | NR1I2 (0.37) | NR1I2KDM4ETSHRHSD17B10PDCD1 | |
| SCHEMBL17039260 | 0.84 | NR1I2 (0.50) | NR1I2KCNH2AVPR1B | |
| SCHEMBL17029021 | 0.82 | NR1I2 (0.45) | NR1I2PDCD1CD274AVPR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3107913-B1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2018-07-04 | — | — | EP | disclosed |
| EP-3107913-B1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2018-07-04 | — | — | EP | disclosed |
| US-9938271-B2 | Inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2018-04-10 | — | — | US | disclosed |
| US-9938271-B2 | Inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2018-04-10 | — | — | US | disclosed |
| US-20170008887-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY | 2017-01-12 | — | — | US | disclosed |
| US-20170008887-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY | 2017-01-12 | — | — | US | disclosed |
| EP-3107913-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE (NO.5) LIMITED (GB) | 2016-12-28 | — | — | EP | disclosed |
| WO-2015126765-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-08-27 | — | — | WO | disclosed |
| WO-2015126765-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170008887-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, RTF2, MAVS | NR1I2 3085/4885XPO1 1034/4885KDM4E 2143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.